Zimmer Biomet (ZBH) Gives Up 15% on Weak Q3

Core Viewpoint - Zimmer Biomet Holdings, Inc. (NYSE:ZBH) experienced a significant decline in stock price, dropping 15.15% to $87.55, due to disappointing organic sales growth forecasts and weak earnings performance in Q3 [1][3]. Financial Performance - In Q3, Zimmer Biomet's net income decreased by 7.3% to $230.9 million from $249.1 million year-on-year [3]. - Net sales increased by 9.7% to $2 billion compared to $1.8 billion in the same period last year [3]. Growth Outlook - The company maintained its overall revenue growth forecast but revised its organic growth outlook down to 4% to 4.5% due to last-minute order cancellations [2]. - The US market showed strong performance with a 5.6% organic revenue growth, driven by the adoption of new products known as the 'Magnificent Seven' [4]. Product Innovations - Zimmer Biomet is preparing to launch new technologies, including the first fully autonomous robot in orthopedics and an iodine-treated hip implant designed to prevent infections [5].